MedTrace Logo

Safety and Effectiveness Study of Docetaxel and ZD1839 Followed by Removal of the Prostate to Treat Prostate Cancer

NCT00242918 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2012-02-07

No results posted yet for this study

Summary

The purpose of this study is to determine the safety and effectiveness of the combination of docetaxel and ZD1839 on destroying prostate cancer before removal of the prostate.

Conditions

Interventions

DRUG

docetaxel

DRUG

ZD1839

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Sanofi

    collaborator INDUSTRY

  • Benaroya Research Institute

    lead OTHER

Principal Investigators

  • Jacqueline Vuky, MD · Virginia Mason Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-05-31
Completion
2007-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00242918 on ClinicalTrials.gov